CONMED (CNMD)
(Delayed Data from NYSE)
$66.59 USD
+0.03 (0.05%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $66.56 -0.03 (-0.05%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$66.59 USD
+0.03 (0.05%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $66.56 -0.03 (-0.05%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
Zacks News
Here's Why You Should Invest in Surmodics (SRDX) Stock Now
by Zacks Equity Research
Surmodics (SRDX) is gaining from consistent growth In Vitro Diagnostics (IVD) unit and persistent efforts to boost R&D functionalities.
Ecolab (ECL) Expands Product Portfolio With New Technology
by Zacks Equity Research
Ecolab (ECL) made an enhancement in its healthcare offerings with new technology that will improve standard of care for hospitals.
Here's Why You Should Hold on to Cardinal Health (CAH) Stock
by Zacks Equity Research
Cardinal Health (CAH) is gaining from diversified product portfolio and robust pharmaceutical segment. However, integration risks remain a concern.
What's in Store for Cooper Companies (COO) in Q3 Earnings?
by Zacks Equity Research
Better-than-expected performance at CVI and CSI and higher revenues are likely to aid Cooper Companies (COO) in Q3 earnings.
CONMED (CNMD) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Higher revenues, solid segmental performance and strong adjusted gross margins benefit CONMED's (CNMD) Q2 earnings. However, high long-term debt remains a concern.
Conmed (CNMD) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Conmed (CNMD) delivered earnings and revenue surprises of 5.66% and 2.22%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Conmed (CNMD) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Conmed (CNMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LH vs. CNMD: Which Stock Is the Better Value Option?
by Zacks Equity Research
LH vs. CNMD: Which Stock Is the Better Value Option?
Here's Why You Should Invest in CONMED (CNMD) Stock Now
by Zacks Equity Research
CONMED (CNMD) continues to benefit from robust international sales, broad product portfolio and persistent focus on R&D.
Myriad Genetics' Elevate 2020 Plan Holds Promise Amid Issues
by Zacks Equity Research
Myriad Genetics (MYGN) unveils an 'Elevate 2020' program that aims to generate $50 million in incremental operating income by fiscal 2020.
Medtronic's Titan Spine Buyout to Boost Spine Surgery Range
by Zacks Equity Research
Medtronic's (MDT) comprehensive biologics portfolio clubbed with Titan Spine's surface-enhanced titanium implants can enhance patient outcomes in spinal procedures.
Walgreens Gains on Strategic Deals, Margin Pressure Remains
by Zacks Equity Research
Walgreens Boots' (WBA) Retail Pharmacy USA division is witnessing comparable prescription growth and also benefiting from a strong retail prescription market.
Thermo Fisher's Unit Sale May Not Ail Specialty Diagnostics
by Zacks Equity Research
The Anatomical Pathology business of Thermo Fisher (TMO) belongs to its Specialty Diagnostics segment that serves customers across healthcare and clinical laboratories.
Here's Why You Should Hold Varian Medical (VAR) Stock Now
by Zacks Equity Research
Varian (VAR) expects the Cancer Treatment Services International buyout to prove accretive to earnings per share during fiscal 2021.
Amedisys Rides on New Buyouts, Strength in Personal Care Arm
by Zacks Equity Research
Amedisys' (AMED) recently-integrated Personal Care segment is attaining stability and living up to expectation.
Veeva's Vault eTMF Implemented by South Korea's Celltrion
by Zacks Equity Research
Management at Veeva (VEEV) expects Vault subscription revenues to grow a significant 40% in fiscal 2020.
Patterson Companies' (PDCO) Earnings Miss Estimates in Q4
by Zacks Equity Research
Patterson Companies' (PDCO) Q4 results benefit from higher revenues, gross margin expansion and solid show by Animal Health segment.
Varian (VAR) & Tennessee Oncology to Implement Use of Noona
by Zacks Equity Research
Varian's (VAR) core Oncology unit gets a boost from the latest collaboration with Tennessee Oncology.
Here's Why You Should Invest in DENTSPLY SIRONA (XRAY) Now
by Zacks Equity Research
DENTSPLY (XRAY) focuses on innovation through active R&D.
Veeva's Submissions & RIM Implemented by Sumitomo Dainippon
by Zacks Equity Research
Veeva's (VEEV) flagship Vault platform witnesses robust demand.
Here's Why You Should Buy Masimo (MASI) Stock Right Now
by Zacks Equity Research
Masimo (MASI) receives FDA clearance for its O3 Regional Oximetry for utilization on neonatal and infant patients.
DaVita Divests DMG to Optum, Boosts Kidney Care Services
by Zacks Equity Research
The divestment of DMG boosts DaVita's (DVA) core Kidney Care business.
Here's Why You Should Hold PerkinElmer (PKI) Stock for Now
by Zacks Equity Research
PerkinElmer (PKI) raises earnings per share guidance for 2019.
Here's Why You Should Hold Baxter International (BAX) for Now
by Zacks Equity Research
Baxter (BAX) expects its bottom line to rise in the second quarter of 2019, courtesy to Renal Care and Clinical Nutrition businesses.
Here's Why Conmed (CNMD) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does Conmed (CNMD) have what it takes to be a top stock pick for momentum investors? Let's find out.